Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity

Manuel Cobo,1 Vanesa Gutiérrez,1 Rosa Villatoro,2 Jose Manuel Trigo,1 Inmaculada Ramos,1 Omar López,1 María Ruiz,1 Ana Godoy,1 Irene López,1 Macarena Arroyo3 1Medical Oncology Department, Hospital Universitario Málaga Regional y Virgen de la Vic...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Cobo M, Gutiérrez V, Villatoro R, Trigo JM, Ramos I, López O, Ruiz M, Godoy A, López I, Arroyo M
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2017
Materias:	Ramucirumab NSCLC antiangiogenesis VEGF-targeted therapy second line therapy. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
Acceso en línea:	https://doaj.org/article/9ce6e473f41f4ac5838784a2d4df92bc
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:9ce6e473f41f4ac5838784a2d4df92bc
record_format	dspace
spelling	oai:doaj.org-article:9ce6e473f41f4ac5838784a2d4df92bc2021-12-02T02:41:05ZSpotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity1179-2728https://doaj.org/article/9ce6e473f41f4ac5838784a2d4df92bc2017-07-01T00:00:00Zhttps://www.dovepress.com/spotlight-on-ramucirumab-in-the-treatment-of-nonsmall-cell-lung-cancer-peer-reviewed-article-LCTThttps://doaj.org/toc/1179-2728Manuel Cobo,1 Vanesa Gutiérrez,1 Rosa Villatoro,2 Jose Manuel Trigo,1 Inmaculada Ramos,1 Omar López,1 María Ruiz,1 Ana Godoy,1 Irene López,1 Macarena Arroyo3 1Medical Oncology Department, Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA, 2Medical Oncology Department, Hospital Costa del Sol, Marbella, IBIMA, 3Pneumology Department, Hospital Universitario Málaga Regional, IBIMA, Málaga, Spain Abstract: The vascular endothelial growth factor (VEGF) and receptor is a therapeutic target because of the importance of this pathway in carcinogenesis. This pathway regulates and promotes angiogenesis as well as increases endothelial cell proliferation, permeability, and cancer survival. Ramucirumab is a new fully human monoclonal antibody that targets the VEGF receptor-2, an important key receptor implicated in angiogenesis. Ramucirumab has been approved for the treatment of second-line advanced or metastatic non-small cell lung cancer (NSCLC) in combination with the chemotherapy agent docetaxel. This was based on the result of the randomized trial REVEL of 1,253 patients with metastatic NSCLC previously treated with a platinum-based combination therapy. The authors observed a significant improvement in overall survival (OS) with an acceptable toxicities profile. In this study, patients were randomized to receive ramucirumab plus docetaxel or placebo with docetaxel. The combination of docetaxel and ramucirumab showed an improved OS (hazard ratio [HR]: 0.86; 95% CI: 0.75, 0.98). Median OS was 10.5 months in the ramucirumab arm versus 9.1 months in the placebo arm. Regarding side effects, the toxicity described on the ramucirumab arm were principally diarrhea, fatigue, and neutropenia. The most common (5%) adverse reactions of grade 3 and 4 in the ramucirumab arm were fatigue, neutropenia, febrile neutropenia, leukopenia, and hypertension. Adding ramucirumab to docetaxel improves QoL of patients, and does not impair symptoms or functioning. There are currently several trials in progress evaluating the effects of ramucirumab in combination with other drugs in patients with advanced NSCLC. Keywords: ramucirumab, NSCLC, antiangiogenesis, VEGF-targeted therapy, pretreatedCobo MGutiérrez VVillatoro RTrigo JMRamos ILópez ORuiz MGodoy ALópez IArroyo MDove Medical PressarticleRamucirumabNSCLCantiangiogenesisVEGF-targeted therapysecond line therapy.Neoplasms. Tumors. Oncology. Including cancer and carcinogensRC254-282ENLung Cancer: Targets and Therapy, Vol Volume 8, Pp 57-66 (2017)
institution	DOAJ
collection	DOAJ
language	EN
topic	Ramucirumab NSCLC antiangiogenesis VEGF-targeted therapy second line therapy. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282
spellingShingle	Ramucirumab NSCLC antiangiogenesis VEGF-targeted therapy second line therapy. Neoplasms. Tumors. Oncology. Including cancer and carcinogens RC254-282 Cobo M Gutiérrez V Villatoro R Trigo JM Ramos I López O Ruiz M Godoy A López I Arroyo M Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
description	Manuel Cobo,1 Vanesa Gutiérrez,1 Rosa Villatoro,2 Jose Manuel Trigo,1 Inmaculada Ramos,1 Omar López,1 María Ruiz,1 Ana Godoy,1 Irene López,1 Macarena Arroyo3 1Medical Oncology Department, Hospital Universitario Málaga Regional y Virgen de la Victoria, IBIMA, 2Medical Oncology Department, Hospital Costa del Sol, Marbella, IBIMA, 3Pneumology Department, Hospital Universitario Málaga Regional, IBIMA, Málaga, Spain Abstract: The vascular endothelial growth factor (VEGF) and receptor is a therapeutic target because of the importance of this pathway in carcinogenesis. This pathway regulates and promotes angiogenesis as well as increases endothelial cell proliferation, permeability, and cancer survival. Ramucirumab is a new fully human monoclonal antibody that targets the VEGF receptor-2, an important key receptor implicated in angiogenesis. Ramucirumab has been approved for the treatment of second-line advanced or metastatic non-small cell lung cancer (NSCLC) in combination with the chemotherapy agent docetaxel. This was based on the result of the randomized trial REVEL of 1,253 patients with metastatic NSCLC previously treated with a platinum-based combination therapy. The authors observed a significant improvement in overall survival (OS) with an acceptable toxicities profile. In this study, patients were randomized to receive ramucirumab plus docetaxel or placebo with docetaxel. The combination of docetaxel and ramucirumab showed an improved OS (hazard ratio [HR]: 0.86; 95% CI: 0.75, 0.98). Median OS was 10.5 months in the ramucirumab arm versus 9.1 months in the placebo arm. Regarding side effects, the toxicity described on the ramucirumab arm were principally diarrhea, fatigue, and neutropenia. The most common (5%) adverse reactions of grade 3 and 4 in the ramucirumab arm were fatigue, neutropenia, febrile neutropenia, leukopenia, and hypertension. Adding ramucirumab to docetaxel improves QoL of patients, and does not impair symptoms or functioning. There are currently several trials in progress evaluating the effects of ramucirumab in combination with other drugs in patients with advanced NSCLC. Keywords: ramucirumab, NSCLC, antiangiogenesis, VEGF-targeted therapy, pretreated
format	article
author	Cobo M Gutiérrez V Villatoro R Trigo JM Ramos I López O Ruiz M Godoy A López I Arroyo M
author_facet	Cobo M Gutiérrez V Villatoro R Trigo JM Ramos I López O Ruiz M Godoy A López I Arroyo M
author_sort	Cobo M
title	Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
title_short	Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
title_full	Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
title_fullStr	Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
title_full_unstemmed	Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
title_sort	spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity
publisher	Dove Medical Press
publishDate	2017
url	https://doaj.org/article/9ce6e473f41f4ac5838784a2d4df92bc
work_keys_str_mv	AT cobom spotlightonramucirumabinthetreatmentofnonsmallcelllungcancerdesigndevelopmentandclinicalactivity AT gutierrezv spotlightonramucirumabinthetreatmentofnonsmallcelllungcancerdesigndevelopmentandclinicalactivity AT villatoror spotlightonramucirumabinthetreatmentofnonsmallcelllungcancerdesigndevelopmentandclinicalactivity AT trigojm spotlightonramucirumabinthetreatmentofnonsmallcelllungcancerdesigndevelopmentandclinicalactivity AT ramosi spotlightonramucirumabinthetreatmentofnonsmallcelllungcancerdesigndevelopmentandclinicalactivity AT lopezo spotlightonramucirumabinthetreatmentofnonsmallcelllungcancerdesigndevelopmentandclinicalactivity AT ruizm spotlightonramucirumabinthetreatmentofnonsmallcelllungcancerdesigndevelopmentandclinicalactivity AT godoya spotlightonramucirumabinthetreatmentofnonsmallcelllungcancerdesigndevelopmentandclinicalactivity AT lopezi spotlightonramucirumabinthetreatmentofnonsmallcelllungcancerdesigndevelopmentandclinicalactivity AT arroyom spotlightonramucirumabinthetreatmentofnonsmallcelllungcancerdesigndevelopmentandclinicalactivity
_version_	1718402308081975296

Spotlight on ramucirumab in the treatment of nonsmall cell lung cancer: design, development, and clinical activity

Ejemplares similares